Comparación de la elastografía hepática por ARFI y los índicesserológicos APRI y FIB-4 en la evaluación no invasiva de la fibrosishepática en adultos

Elizabeth Tavarez M.; Fernando Contreras; Nela Perez

Authors

Elizabeth Tavarez M. Centro de Diagnóstico Medicina Avanzada y Telemedicina (CEDIMAT) Santo Domingo, Dominican Republic.
Fernando Contreras Centro de Diagnóstico Medicina Avanzada y Telemedicina (CEDIMAT) Santo Domingo, Dominican Republic.
Nela Perez Centro de Diagnóstico Medicina Avanzada y Telemedicina (CEDIMAT) Santo Domingo, Dominican Republic.

Keywords:

Liver fibrosis, elastography, ARFI, APRI, FIB-4

Abstract

Liver fibrosis is the main prognostic determinant of chronic liver diseases. Liver biopsy, although considered the gold standard, has limitations that have driven the development of non-invasive methods such as liver elastography and serological indices. Objective: To compare acoustic pulse force elastography (ARFI) with the serological indices APRI and FIB-4 in the non-invasive assessment of liver fibrosis. Methods: Observational, descriptive, retrospective, and cross-sectional study conducted in adults using ARFI liver elastography and laboratory tests for calculating APRI and FIB-4, performed no more than 30 days apart. Descriptive statistics and normality tests were applied. Results: Ninety-two patients were included, with a mean age of 58.7 ± 13 years; 55.4% were male. The mean liver stiffness measured by ARFI was 6.62 kPa. Most patients were classified into minimal or mild fibrosis stages using all three methods evaluated, with no significant differences according to sex. Conclusions: ARFI liver elastography and the APRI and FIB-4 indices show clinical agreement useful for the non-invasive assessment of liver fibrosis, constituting complementary tools in clinical practice.

References

1. Friedman SL. Liver fibrosis — from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–S53.

2. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2021;75(3):659–689.

3. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017–1044.

4. Nightingale K. Acoustic Radiation Force Impulse (ARFI) imaging: a review. Curr Med Imaging Rev. 2011;7(4):328–339.

5. Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: A pooled meta-analysis. J Viral Hepat. 2012;19(2):e212–219.

6. Saavedra D, Méndez A, Ramírez M, Loor C, Moreira L. Utilidad de la elastografía por ARFI en la evaluación de la fibrosis hepática. Rev Gastroenterol Latinoam. 2019;50(3):215–223.

7. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.

8. Shah AG, Lydecker A, Murray K, Tetri B, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112.

9. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281.e4.

10. McPherson S, Hardy T, Dufour J‑F, Petta S, Romero‑Gómez M, Allison M, et al. Age as a confounding factor for the accurate non‑invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751.

11. Tengan FM, Abdala E, Nascimento M, Bernardo WM, Barone AA. Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):587.

12. Johnston LG, Vaillant TC, Dolores Y, Vales HM. HIV, hepatitis B/C and syphilis prevalence and risk behaviors among gay, transsexuals and men who have sex with men, Dominican Republic. Int J STD AIDS. 2013;24(4):313–321.

13. Ferraioli G, Barr RG. Ultrasound liver elastography beyond liver fibrosis assessment. World J Gastroenterol. 2020 Jun 28;26(24):3413–3420.

14. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of NAFLD—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

15. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–851.

16. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(8):756–768.

17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (FIB-4). Hepatology. 2006;43(6):1317–1325.